Neuroscience: Sensing calcium in red

Nina Vogt

DOI: https://doi.org/10.1038/NMETH.3888

IF: 48

2016-05-31

Nature Methods

Abstract:

What problem does this paper attempt to address?

Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease

Yueh-Lung Peng,You-Lin Tain,Chien-Te Lee,Yi-Hsn Yang,Yaw-Bin Huang,Yen-Hsia Wen,Chien-Ning Hsu

DOI: https://doi.org/10.1038/s41598-020-67026-1

IF: 4.6

2020-07-01

Scientific Reports

Abstract:Abstract Whether the clinical trial treatment effect of urate-lowering therapy (ULT) in patient with chronic kidney disease (CKD) is generalizable to real-word settings is unclear. This study aimed to compare febuxostat with allopurinol for uric acid reduction and renal protection in patients with CKD. Adult CKD patients newly treated with ULT were identified using electronic health records from 2010 to 2015 from a large healthcare delivery system in Taiwan. Patients with renal replacement therapy or undergoing ULT for <3 months were excluded. Propensity score–matched cohort study design was conducted to compare outcomes between patients initiated with febuxostat or allopurinol therapy. Cox regression analyses were employed to compare the adjusted hazards ratio (aHR) of incident event of estimated glomerular filtration rate (eGFR) ≥ 30% decrease, and the difference in longitudinal changes in serum uric acid (SUA) and eGFR between groups was analyzed using linear mixed model. Overall, 1050 CKD patients who initiated febuxostat (n = 525) or allopurinol (n = 525) treatment were observed for 2.5 years. Compared with allopurinol, febuxostat use was associated with higher rate of patients maintaining SUA target 80% of follow-up time with a reduction in mean SUA change. There were no significant differences in the mean eGFR changes over time between the febuxostat and allopurinol groups or in the risk of eGFR decline ≥30% of baseline. Febuxostat was associated with greater reduction in SUA level than allopurinol in patients with CKD. However, febuxostat and allopurinol showed no difference in renal function changes during study follow-up. These findings require further investigation with long-term follow up in CKD patients with hyperuricemia.

multidisciplinary sciences
Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta‐analysis

Jian‐hao Deng,Peng‐hui Lai,Li‐shan Xie,Shu‐sheng Qiu,De‐sheng Qiu,Jia‐xing Zhang

DOI: https://doi.org/10.1111/cts.13757

2024-03-17

Clinical and Translational Science

Abstract:The cardiovascular (CV) safety of febuxostat compared to allopurinol for the treatment of hyperuricemia among Asian patients is uncertain. In this study, we conducted a systematic review and meta‐analysis to compare the CV safety profiles of febuxostat with allopurinol in Asian patients with hyperuricemia. A total of 13 studies were included. On the basis of the pooled results of cohort studies, febuxostat users were at a significantly higher risk for acute coronary syndrome (ACS; hazard ratio [HR]: 1.06, 95% confidence interval [CI]: 1.03–1.09, p

medicine, research & experimental
Urate‐lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink

Steven J. Kiddle,Karolina Andersson Sundell,Shira Perl,Stephen Nolan,Magnus Bjursell

DOI: https://doi.org/10.1002/clc.24297

2024-06-16

Clinical Cardiology

Abstract:Background Elevated serum uric acid (sUA) is associated with heart failure (HF). Hypothesis Urate‐lowering therapy (ULT) in HF is associated with lower risk of HF hospitalization (hHF) and mortality. Methods Data on patients with HF and gout or hyperuricemia in the Clinical Practice Research Datalink database linked to the Hospital Episode Statistics and the Office for National Statistics in the United Kingdom were analyzed. Risks of hHF and all‐cause mortality or cardiovascular‐related mortality by ULT exposure (ULT initiated within ≤6 months of gout or hyperuricemia diagnosis) were analyzed in a propensity score‐matched cohort using adjusted Cox proportional hazards regression models. Results Of 2174 propensity score‐matched pairs, patients were predominantly male, aged >70 years, with mean ± standard deviation sUA 9.3 ± 1.8 (ULT‐exposed) and 9.4 ± 1.9 mg/dL (ULT‐unexposed). At 5 years, ULT‐exposed patients had a 43% lower risk of hHF or all‐cause mortality (adjusted hazard ratio [HR]: 0.57; 95% confidence interval [CI]: 0.51–0.65) and a 19% lower risk of hHF or cardiovascular‐related mortality (adjusted HR: 0.81; 95% CI: 0.71–0.92) versus no ULT exposure. Conclusion ULT was associated with reduced risk of adverse clinical outcomes in patients with HF and gout or hyperuricemia over 5 years.

cardiac & cardiovascular systems
Organization of the infraorbital nerve in rat: a quantitative electron microscopic study

M. Jacquin,A. Hess,G. Yang,Peter Adamo,R. Rhoades

DOI: https://doi.org/10.1016/0006-8993(84)90742-X

IF: 3.61

1984-01-02

Brain Research

Abstract:
Effect of febuxostat on adverse events and mortality in gout in Taiwan: An interrupted time series analysis

Ping‐Han Tsai,Chang‐Fu Kuo,Jia‐Rou Liu,Pei‐Ru Li,Lai‐Chu See

DOI: https://doi.org/10.1111/1756-185X.14558

2023-01-08

International Journal of Rheumatic Diseases

Abstract:Objectives To evaluate the influence of febuxostat on adverse events and mortality in gout. Methods We retrospectively enrolled patients with newly diagnosed gout and prescribed urate‐lowering therapy between 2006 and 2017 from the Taiwan National Health Insurance Database. These patients were divided into 2 groups: with and without comorbidities (n = 294 847 and 194 539). An interrupted time series analysis with adjustments for demographics, comorbidities, and comedication by propensity score‐based stabilized weights was used to compare the trend of adverse events and mortality before vs after febuxostat was introduced in 2012. Results The proportion of febuxostat use gradually increased from 0% in 2012 to 30% in those with comorbidities and 10% in those without comorbidities in 2017. Allopurinol use decreased from 30% in 2012 to 10% in 2017. The slope of the 1‐year incidence rate of Stevens–Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) (per 10 000 patients) significantly reduced after 2012 in those with and without comorbidities (−0.375 per quarter, P = .015 and −.253 per quarter, P = .049). The slope of the 3‐year incidence rate of acute myocardial infarction (AMI) (per 1000 patients), percutaneous coronary intervention (PCI) (per 1000 patients), and all‐cause mortality (per 100 patients) significantly increased after 2012 in those with comorbidities (+0.207 per quarter, P = .013; +.389 per quarter, P = .002; +.103 per quarter, P = .001). Conclusions Febuxostat may reduce SJS and TEN in all gout patients but increase AMI, PCI, and all‐cause mortality in gout patients with comorbidities.

rheumatology
An Allopurinol-Controlled, Multicenter, Randomized, Double-Blind, Parallel Between-Group, Comparative Study Of Febuxostat In Chinese Patients With Gout And Hyperuricemia

Xinfang Huang,Hui Du,Jieruo Gu,Dongbao Zhao,Lindi Jiang,Xinfu Li,Xiaoxia Zuo,Yi Liu,Zhanguo Li,Xiangpei Li,Ping Zhu,Juan Li,Zhiyi Zhang,Anbin Huang,Yuanchao Zhang,Chunde Bao

DOI: https://doi.org/10.1111/1756-185X.12266

2014-01-01

International Journal of Rheumatic Diseases

Abstract:Aim: Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, has been identified as a potential alternative to allopurinol in patients with hyperuricemia. The purpose of this study was to compare the urate-lowering (UL) efficacy and safety of daily febuxostat and allopurinol in Chinese gout patients with hyperuricemia.Methods: Gout patients (n = 512) with serum uric acid (sUA) concentrations of at least 8.0 mg/dL were randomized to receive daily febuxostat 40 mg or 80 mg or allopurinol 300 mg for 28 weeks. Prophylaxis against gout flares with meloxicam or colchicine was provided during weeks 1 through 8. The primary endpoint was the percentage of subjects achieving a sUA concentration of < 6.0 mg/dL at the last three monthly measurements.Results: The primary endpoint was reached in 44.77% of patients receiving 80 mg of febuxostat, 27.33% of those receiving 40 mg of febuxostat, and 23.84% of those receiving allopurinol. The UL efficacy in the febuxostat 80 mg group was higher than in the allopurinol (P < 0.0001) and febuxostat 40 mg (P = 0.0008) groups. The UL efficacy of the febuxostat 40 mg group was statistically non-inferior to that of the allopurinol group. No significant change in the number of tophi was observed during the final visit relative to baseline in each treatment group. The rate of gout flares requiring treatment from weeks 9 through 28 and the incidence of adverse events was similar among treatment groups.Conclusions: The UL efficacy of daily febuxostat 80 mg was greater than that of febuxostat 40 mg and allopurinol 300 mg, which exhibited comparable UL efficacy. Safety of febuxostat and allopurinol was comparable at the doses tested.
Evaluation of febuxostat initiation during an acute gout attack: A prospective, randomized clinical trial

Ruixia Sun,Jie Lu,Hui Li,Xiaoyu Cheng,Ying Xin,Changgui Li

DOI: https://doi.org/10.1016/j.jbspin.2020.03.017

IF: 5.263

2020-10-01

Joint Bone Spine

Abstract:Objective: Urate-lowering treatment (ULT) is recommended in gout management. However, initiation of ULT during an acute gout flare is still inconclusive. This study aimed to evaluate the efficacy and safety of the ULT febuxostat administered at initiation of an acute gout attack.Methods: A prospective randomized controlled clinical trial was conducted for 12 weeks in primary gout patients who were admitted with acute gout attacks. Subjects were randomly assigned to the febuxostat group in which febuxostat, 40 mg daily, was administered in the primary care setting for attacks, or to the control group in which febuxostat, 40 mg daily, was administered after the attacks. All patients received adequate anti-inflammatory and analgesic therapies. Serum urate (SU) levels were monitored throughout the study. Pain, measured using a visual analogue scale (VAS), and gout recurrence rate were used as primary outcomes. Flare-related inflammation biomarkers were selected as secondary outcomes.Results: Fifty-two patients completed the study (febuxostat group: n = 28; control group: n = 24). No significant differences were detected in VAS scores between the two groups over the first 14-day observation period (P > 0.05). Administration of febuxostat decreased SU levels significantly during the first 2-week period. However, the gout recurrent rate or gout flare-related inflammation indicators did not change in the febuxostat or control groups. Treatment-related adverse events were mild and similar between groups.Conclusion: Initiation of the urate-lowering drug febuxostat during an acute gout attack caused no significant difference in daily pain, recurrent flares, or adverse effects. The treatment significantly decreased SU levels in the early stage and might have potential long-term benefits in these patients.

rheumatology
Febuxostat Therapy for Patients with Gout and Stage 2-4 CKD: a Retrospective Study

Peiyu Zhang,Mo Chen,Jundi Wang,Shunjie Hu,Xiaoyong Lu,Huaxiang Wu

DOI: https://doi.org/10.1007/s40744-022-00480-7

Abstract:Introduction: The aim of this study is to explore the efficacy and renal safety of febuxostat in gout and stage 2-4 chronic kidney disease (CKD) and factors that correlated with target serum urate (SU). Methods: A single-center retrospective study including male patients with gout and CKD was conducted. SU, the rate of SU < 360 µmol/L (RAT), and renal safety were analyzed in subjects who received febuxostat over 44 weeks. Factors that correlated with target SU were also explored. Results: Between January 2017 and March 2021, 102 patients (stage 2 CKD: n = 27; stage 3 CKD: n = 70; stage 4 CKD: n = 5) were enrolled. The SU level reduced significantly over 44 weeks (600.76 ± 95.42 versus 405.52 ± 111.93 µmol/L; P < 0.05), and RAT increased to 39.20%. The overall estimated glomerular filtration rate (eGFR) level improved over 44 weeks (52.05 ± 11.68 versus 55.46 ± 14.49 mL/min/1.73 cm2, P < 0.05). An obvious improvement of eGFR was observed in stage 3 CKD, in patients with ≤ 1 risk factor (hypertension, diabetic mellitus, hyperlipidemia, or usage of non-steroidal anti-inflammatory drugs), and in patients with terminal SU < 360 µmol/L (P < 0.05). Logistic regression analysis indicated that baseline SU level and body weight were correlated with RAT. Further analysis revealed that patients with SU < 600 μmol/L and body weight ≤ 70 kg reached higher RAT (56.7%). Conclusions: Febuxostat demonstrated efficacy and renal safety in patients with gout and CKD in clinical practice. Achieving the target SU could obviously improve renal function. Baseline SU level and body weight could affect the achievement of target SU.
A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout

Fengchun Zhang,Zhichun Liu,Lindi Jiang,Hao Zhang,Dongbao Zhao,Yang Li,Hejian Zou,Xiaoyue Wang,Xiangpei Li,Bingyin Shi,Jianhua Xu,Hongjie Yang,Shaoxian Hu,Shen Qu

DOI: https://doi.org/10.1007/s40744-019-00173-8

2019-01-01

Rheumatology and Therapy

Abstract:Introduction This 24-week randomized, double-blind, non-inferiority study compared the efficacy and safety of febuxostat, a xanthine oxidase inhibitor, with allopurinol using an up-titration method in hyperuricemic Chinese subjects with or without gout. Methods Eligible adults (serum uric acid [SUA] > 7.0 mg/dl with a history of gout, SUA ≥ 8.0 mg/dl with complications or SUA ≥ 9.0 mg/dl without complications) were randomized (1:1:1) to febuxostat 40 mg/day, 80 mg/day, or allopurinol 300 mg/day. Starting doses of febuxostat 20 mg/day and allopurinol 100 mg/day were up-titrated, up to 16 weeks, to the randomized doses and maintained to week 24. Primary endpoint was non-inferiority of febuxostat 40 mg/day versus allopurinol 300 mg/day based on the percentage of subjects with SUA ≤ 6.0 mg/dl at week 24. The same comparison was made between febuxostat 60 mg/day or 80 mg/day versus allopurinol 300 mg/day. Safety assessments included measurement of treatment-emergent adverse events (TEAEs). Results The per-protocol population comprised 472 subjects. Non-inferiority of febuxostat 40 mg/day versus allopurinol 300 mg/day was not demonstrated based on the protocol-defined margin of − 10% (44.7 vs. 50.0%; − 5.3% difference; 95% confidence interval [CI]: − 16.4%, 5.8%); however, superiority over allopurinol 300 mg/day was demonstrated for febuxostat 60 mg/day at week 16 (66.3 vs. 51.2%; a 15.0% difference; 95% CI: 4.2%, 25.9%) and febuxostat 80 mg/day at week 24 (70.0 vs. 50.0%; a 20.0% difference; 95% CI: 9.3%, 30.7%). The frequency of TEAEs was similar across groups, with gout flares occurring frequently. Conclusions Using a novel dose-titration method, although the primary endpoint of non-inferiority of febuxostat 40 mg/day versus allopurinol 300 mg/day was not reached, non-inferiority and superiority of febuxostat 60 mg/day and 80 mg/day versus allopurinol 300 mg/day was demonstrated at weeks 16 and 24, respectively. Febuxostat demonstrated an acceptable tolerability profile in the treatment of hyperuricemia in Chinese subjects with or without gout. Trial Registration JapicCTI-132106. Funding Astellas Pharma Global Development, Inc.
Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis

Li Zhao,Ling Cao,Tian-Yi Zhao,Xue Yang,Xiao-Xia Zhu,He-Jian Zou,Wei-Guo Wan,Yu Xue

DOI: https://doi.org/10.1097/CM9.0000000000000682

IF: 6.133

2020-01-01

Chinese Medical Journal

Abstract:Background Hyperuricemia and gout have become public health concerns; many important guidelines have recommended xanthine oxidase inhibitors (XOIs) as the first-line urate-lowering therapies (ULTs) to treat chronic gout with hyperuricemia. However, whether treating hyperuricemia and gout with ULTs modifies cardiovascular risks remains controversial. The aim of this study was to assess the incident risk of cardiovascular (CV) events (CVE) in hyperuricemia population, assess the cardiovascular benefit-risk of ULTs in hyperuricemia patients with or without gout in diverse cardiovascular risk sub-groups, and specify the safety of different ULTs. Methods We searched PubMed, Embase, the Cochrane Library, Wanfang, Chongqing VIP (CQVIP, en.cqvip.com), and China National Knowledge Infrastructure Database for prospective cohort studies and randomized controlled trials (RCTs) in English and Chinese. Potential medications included XOIs, and uricosurics. RCTs were divided into sub-groups analysis based on blinding status and patients' history of CV diseases. Risk ratios (RRs) were calculated and were reported with corresponding 95% confidence intervals (CIs) by fixed-effects or random-effects model. Results Seven prospective cohort studies and 17 RCT studies were included. The risks of both major adverse cardiovascular events (MACE) (RR = 1.72, 95% CI 1.28-2.33) and CVE (RR = 1.35, 95% CI 1.12-1.62) were higher in the hyperuricemia population than non-hyperuricemia one. In seven RCT studies where XOIs were compared with no-treatment or placebo, the results of five low CV risk studies showed that XOIs lowered the risks of both MACE (RR = 0.35, 95% CI 0.20-0.62) and CVE (RR = 0.61, 95% CI 0.44-0.85); whereas two high CV risk studies showed that XOIs lowered the risk of CVE (RR = 0.69, 95% CI 0.54-0.88) rather than MACE (RR = 0.62, 95% CI 0.29-1.35). In nine RCT studies where the cardiovascular safety between febuxostat and allopurinol were compared, no statistical difference was found in the risk of MACE or CVE. Conclusions The hyperuricemia population does have a higher incidence of CVE, and the results suggested that XOIs might reduce the incidence of MACE and total CVE. In addition, from the perspective of cardiovascular safety, febuxostat equaled allopurinol in our meta-analysis.
Effect and safety of febuxotant versus allopurinol in reducing serum urate in subjects with hyperuricemia and gout:a multi-center,randomized,double-blind,parallel controlled trail

WANG Li-ying,ZHAO Yan,ZHENG Yi,LI Xiao-xia,ZHANG Xiao,XU Jian-hua,WU Hua-xiang,HU Shao-xian,ZHAO Yin-huan,ZHANG Feng-xiao,ZHOU Bin,SU Hou-heng,XIAO Zheng-yu,SUN Rui-hua,WANG Guo-chun

DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2013.07.011

2013-01-01

Abstract:Objective To compare urate-lowering(UL) efficacy and safety of daily febuxotant versus allopurinol and in subjects with gout and serum urate(SUA)≥480 μmol/L in six-month trial.Methods Subjects(n=486) were randomized to febuxotant 40 mg or 80 mg or allopurinol 300 mg.Endpoints included the proportion of all subject with sUA≤360 μmol/L and safety assessment.Results In febuxotant 40 mg,80 mg and allopurinol group,primary endpoint was achieved in 49.06%,65.38% and 43.67%.Febuxotant 40 mg UL was statistically non-inferior to allopurinol,but febuxotant 80 mg was superior to both(P<0.0001).Rates of AEs did not differ aross treatment group.Conclusions Febuxotant 40 mg group UL efficacy is similar to allopurinol group,febuxotant 80 mg group UL efficacy is better than both febuxotant 40 mg group and allopurinol group.Febuxotant 40 mg daily and febuxotant 80 mg daily treatment for 24 weeks is well tolerated.
Superiority of low‐dose benzbromarone to low‐dose febuxostat in a prospective, randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion

Fei Yan,Xiaomei Xue,Jie Lu,Nicola Dalbeth,Han Qi,Qing Yu,Can Wang,Mingshu Sun,Lingling Cui,Zhen Liu,Yuwei He,Xuan Yuan,Ying Chen,Xiaoyu Cheng,Lidan Ma,Hailong Li,Aichang Ji,Shuhui Hu,Zijing Ran,Robert Terkeltaub,Changgui Li

DOI: https://doi.org/10.1002/art.42266

2022-07-19

Abstract:Objective The predominant mechanism driving hyperuricemia in gout is renal uric acid underexcretion, yet the standard urate‐lowering therapy (ULT) recommendation is first line xanthine oxidase inhibition (XOI) irrespective of the cause of hyperuricemia. Here, we conducted a comparative effectiveness clinical trial of first line un‐titrated, low‐dose benzbromarone uricosuric therapy vs. XOI ULT with low‐dose febuxostat in gout with renal uric acid underexcretion. Methods A prospective, randomized, single‐center, open‐labeled trial of men with gout and renal uric acid underexcretion (defined as fractional excretion of urate <5.5% and uric acid excretion ≤600 mg/day/1.73m2) was conducted. We randomly assigned 196 participants to low‐dose benzbromarone 25 mg daily (LDBen) or low‐dose febuxostat 20 mg daily (LDFeb) for 12 weeks. All participants received daily urine alkalization with oral sodium bicarbonate. The primary endpoint was rate of achieving serum urate (SU) target <6 mg/dL. Results More participants in the LDBen group achieved the serum urate target than LDFeb (61% vs. 32%, P<0.001). Adverse events, including gout flares and urolithiasis, did not differ between groups, with the exception of more transaminase elevation in the LDFeb group (LDBen 4% vs. LDFeb 15%, P=0.008). Conclusion Compared to LDFeb, LDBen had superior urate‐lowering and similar safety in the relatively young and healthy patients with gout of renal uric acid underexcretion type.

rheumatology
Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis

Shengzhao Zhang,Ting Xu,Qingyang Shi,Sheyu Li,Ling Wang,Zhenmei An,Na Su

DOI: https://doi.org/10.3389/fmed.2021.698437

IF: 3.9

2021-06-15

Frontiers in Medicine

Abstract:Background: Hyperuricemia is a common metabolic disease and has become a public health problem because of its increasing prevalence and association with comorbidities. Allopurinol and febuxostat are recommended as the first-line treatments for hyperuricemia and gout. But cardiovascular safety between febuxostat and allopurinol is still controversial. The purpose of this study is to compare the cardiovascular safety of XOIs and placebo in hyperuricemic patients with or without gout. Methods: PubMed, Embase via OVID, Cochrane Library, CNKI, Wanfang, and VIP were searched from their earliest records to February 8th 2021. ClinicalTrials.gov was also searched for unpublished data. The reference lists of included studies and relevant review articles investigating the cardiovascular safety of XOIs in hyperuricemia patients are screened for potentially eligible studies. Randomized controlled trials (RCTs) evaluating allopurinol (100~900 mg/d), febuxostat (20~120 mg/d), or placebo for hyperuricemia were included. The outcomes were incidence of MACE, non-fatal MI, non-fatal stroke, and cardiovascular death. We conducted a Bayesian random-effects network meta-analysis on the included randomized controlled trials using the Markov Chain Monte Carlo simulation method. The grading of recommendations assessment, development, and evaluation (GRADE) approach was used to assesses the certainty of the evidence. Results: Ten RCTs with 18,004 participants were included. The network estimates showed that there was no significant difference observed among febuxostat, allopurinol, and placebo regarding outcomes. The certainty of the evidence ranged from very low to moderate. The probabilities of rankings and SUCRA showed that compared to placebo, febuxostat, and allopurinol might prevent adverse cardiovascular events. Conclusion: Febuxostat is not associated with increasing risk of adverse cardiovascular events compared to allopurinol; and compared to placebo, whether febuxostat and allopurinol reduce the risk of adverse cardiovascular events remains uncertain.

medicine, general & internal
The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study

Lei Pang,Xiaomei Xue,Yuwei He,Can Wang,Lin Han,Maichao Li,Han Qi,Changgui Li,Jie Lu

DOI: https://doi.org/10.2147/JIR.S424820

2023-09-08

Abstract:Purpose: Higher baseline serum urate or higher initial urate-lowering medication dose increased risk of gout flares during urate-lowering therapy (ULT) initiation. The decrease in serum urate may play a crucial role in this process. Therefore, we aim to explore the relationship between decrease in serum urate and the risk of gout flares during ULT initiation. Patients and methods: A 12-week prospective cohort study of Chinese male gout patients was conducted at Shandong Provincial Clinical Research Center for Immune Diseases and Gout in China. Patients were grouped by baseline serum urate (7-7.9 mg/dL, 8-8.9 mg/dL and ≥9 mg/dL). All patients received febuxostat 20 mg daily during weeks 0-4, then escalated to 40mg during weeks 4-12 if serum urate >6mg/dL. The main outcomes were the number of gout flares and the decrease in serum urate. Poisson regression was performed. Results: A total of 282 participants were enrolled, of whom 260 completed (84, 87 and 89 in each group) from March 2021 to December 2021. A 44.2% of all participants experienced at least one gout flare. In the multivariate Poisson regression 1, Δ serum urate 0-12 weeks (IRR 1.184, 95% CI, 1.062-1.320; P=0.002), the number of gout flares before treatment 1 year (1.017, 1.010-1.024; P<0.001) and tophus (1.580, 1.023-2.440; P=0.039) were independently associated with the number of gout flares. While in the multivariate Poisson regression 2, baseline serum urate (1.256, 1.050-1.503; P=0.013) and the number of gout flares before treatment 1 year (1.014, 1.007-1.022; P<0.001) were independently associated with the number of gout flares, Δ serum urate 0-12 weeks (1.055, 0.923-1.207; P=0.433) was no longer a risk factor. Conclusion: ULT-induced gout flares depend on the degree of decrease in serum urate, which is affected by baseline serum urate. Higher baseline serum urate and greater decrease in serum urate lead to higher risk of gout flares.
Effect of the Xanthine Oxidase Inhibitor Febuxostat on the Cardio-Ankle Vascular Index in Asymptomatic Patients with Hyperuricemia and Liver Dysfunction: A Sub-Analysis of the PRIZE Study

Yusuke Kawachi,Yuya Fujishima,Hitoshi Nishizawa,Atsushi Tanaka,Hisako Yoshida,Shinichi Niwano,Makoto Suzuki,Iichiro Shimomura,Koichi Node

DOI: https://doi.org/10.5551/jat.65087

2024-10-03

Abstract:Aims: The effect of uric acid (UA)-lowering therapy with xanthine oxidoreductase (XOR) inhibitors on the development of cardiovascular disease requires further investigation. This study aimed to evaluate the long-term effects of febuxostat on arterial stiffness, focusing on liver function. Methods: The PRIZE study involved random assignment of patients with asymptomatic hyperuricemia to receive either add-on febuxostat treatment (febuxostat group) or non-pharmacological treatment (control group). Of the 514 participants, 23 and 14 patients in the febuxostat and control groups, respectively, underwent assessment of arterial stiffness using the cardio-ankle vascular index (CAVI). The participants in each group were further grouped on the basis of their baseline alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels (above or below the media value or 30 U/L). The primary endpoint was the change in the CAVI from baseline to 12 and 24 months. Results: Overall, no significant differences were found between the control and febuxostat groups in the least-squares mean estimates of changes in CAVI at 24 months (mean between-group difference, -0.41 [95% CI, -1.05 to 0.23]; p=0.204). However, there were significant differences in participants with higher baseline ALT or AST levels above 30 U/L at 24 months (mean between-group difference, -1.12 [95% CI, -2.23 to -0.01]; p=0.048 for ALT ≥ 30 U/L and -1.08 [95% CI, -2.13 to -0.03]; p=0.044 for AST ≥ 30 U/L). Conclusions: Two-year treatment with febuxostat demonstrated a beneficial effect on CAVI in patients with hyperuricemia and liver dysfunction.
Association Between Febuxostat Use and the Incidence of Cardiovascular Events, Mortality, and Kidney Events in Patients With Chronic Kidney Disease Compared to Allopurinol: A Study Using a Japanese Nationwide Database

Miho Otani,Yuta Nonomiya,Yasutaka Ihara,Ryota Kawai,Satsuki Taniuchi,Hisako Yoshida,Kazuhiko Tsuruya,Ayumi Shintani

DOI: https://doi.org/10.7759/cureus.70351

2024-09-27

Cureus

Abstract:Background Patients with chronic kidney disease (CKD) were excluded in most trials that investigated the effects of urate-lowering agents, such as febuxostat and allopurinol, in hyperuricemic patients. This exclusion leads to uncertainty regarding the efficacy of febuxostat in patients with CKD. Due to the high prevalence of hyperuricemia in patients with CKD, we aimed to assess the effect of febuxostat on improving patient outcomes concerning cardiovascular events and survival compared with those treated with allopurinol among patients with CKD. Methods We conducted a retrospective cohort study using Japanese nationwide administrative data from Jan 1, 2013, to Sep 30, 2020. Patients aged over 60 years diagnosed with CKD were included in this study if they were prescribed either febuxostat or allopurinol. The primary outcome was the occurrence of cardiovascular events including myocardial infarction, stroke, unstable angina requiring urgent revascularization, and all-cause deaths. We estimated hazard ratios (HR) and 95% CI using a Cox proportional hazard regression model adjusted for comorbidities, medications, and laboratory data. We also assessed defined starting kidney replacement therapy as a secondary endpoint treating death as a competing risk using the Fine & Gray regression model. Results A total of 21,015 patients included those with febuxostat (n=17,796) and those with allopurinol (n=3,219). The association between the type of drug and the occurrence of cardiovascular events did not show a significant difference (0.107 vs. 0.116 events per patient-year; adjusted HR 0.953, 95% CI: 0.854 to 1.062, P=0.381). Similar results were seen for all-cause deaths (0.060 vs. 0.068 events per patient-year; adjusted HR 0.877, 95% CI: 0.760 to 1.012, P=0.073). Regarding the secondary endpoint, the association between the type of drug and the timing of starting kidney replacement therapy did not show a significant difference (0.118 vs. 0.097 events per patient-year; adjusted HR 0.953, 95% CI: 0.854 to 1.062, P=0.425). Conclusion The use of febuxostat was neither associated with a decreased risk of cardiovascular events or deaths nor with the timing of starting kidney replacement therapy compared to the use of allopurinol in patients with CKD.
Cardiovascular Safety of Febuxostat in Patients With Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials

Roba Ghossan,Ouidade Aitisha Tabesh,Fouad Fayad,Pascal Richette,Thomas Bardin

DOI: https://doi.org/10.1097/RHU.0000000000002045

2024-03-01

Abstract:Introduction: To this date, a causal relationship between febuxostat and cardiovascular disease remains controversial as comparison between trials can be challenging and may lead to misleading conclusions, especially when facing heterogeneous cardiovascular outcomes. We aimed to compare the cardiovascular outcomes in the most pertinent trials of febuxostat compared with controls. Methods: We searched electronic databases using a PICOS-style approach search strategy of randomized controlled trials (RCTs) on cardiovascular outcomes of febuxostat in patients with gout or hyperuricemia. We conducted a quality and risk of bias assessment of the included clinical trials. The definition of major adverse cardiovascular event as well as all reported cardiovascular outcomes were retrieved from every involved trial. Results: Of the 1173 records identified from all sources, 20 RCTs were included in the analysis. The mean duration of follow-up was 69.7 ± 81.5 weeks, and febuxostat dose ranged from 10 to 240 mg with 80 mg being the most commonly used dosage. Overall, the quality of evidence deriving from all RCTs showed concerns in most studies (65%). Major adverse cardiovascular event was defined in 7 of the 20 RCTs (35%), and cardiovascular outcome reporting was very heterogeneous. Overall, the data of cardiovascular safety of febuxostat were reassuring. Conclusions: Our systematic review showed high level of concerns in quality assessment domains as well heterogeneous cardiovascular outcomes across included studies. Cardiovascular outcomes in the majority of White males with gout treated with febuxostat were reassuring when compared with allopurinol. Further studies are needed to draw conclusions in patients with severe cardiovascular disease.
Febuxostat leads to better cardiovascular outcomes compared to allopurinol in patients with advanced chronic kidney disease: A Population-based Cohort Study

Ming-Hsien Tsai,Yun-Yi Chen,Hung-Hsiang Liou,Jing-Tong Wang,Yu-Wei Fang

DOI: https://doi.org/10.1016/j.amjmed.2024.09.018

IF: 5.928

2024-09-29

The American Journal of Medicine

Abstract:Objective Hyperuricemia is a risk factor for cardiovascular disease complications in patients with chronic kidney disease. The impact of febuxostat on cardiovascular disease in advanced chronic kidney disease remains unclear. This study aimed to explore the cardiovascular benefits of xanthine oxidase inhibitors, particularly febuxostat and allopurinol, in patients with advanced chronic kidney disease. Methods A retrospective population-based cohort study was conducted using data from Taiwan's National Health Insurance Research Database (NHIRD) (2006–2017). The TriNetX dataset served as an external validation dataset. The study involved 13,187 patients with advanced chronic kidney disease treated with febuxostat or allopurinol. After propensity score matching, a balanced cohort of 976 patients (488 in each arm) was created. Hazard ratios (HRs) were calculated for all-cause mortality and hospitalizations, utilizing the competing risk regression model. Results Febuxostat was associated with lower all-cause mortality (HR, 0.79; 95% confidence interval [CI], 0.64–0.98) and fewer hospitalizations (HR, 0.53; 95% CI, 0.44–0.63) than allopurinol. After adjustments, febuxostat also reduced hospitalizations for heart failure (HR, 0.59; 95% CI, 0.43–0.80) and infection (HR, 0.65; 95% CI, 0.52–0.82). This cardiovascular benefit of febuxostat was consistently observed in the TriNetX dataset. Moreover, subgroup analysis revealed that febuxostat was better in reducing death and heart failure events than allopurinol across most of the subgroups. Conclusions Febuxostat may confer cardioprotective effects in patients with advanced chronic kidney disease compared with allopurinol, thereby potentially useful in reducing cardiovascular risks in this high-risk population.

medicine, general & internal
Efficacy and safety of febuxostat versus allopurinol in the treatment of gout by Meta analysis

Ting YANG,Min LU,Ying ZHOU,Yi-min CUI

DOI: https://doi.org/10.13699/j.cnki.1001-6821.2015.02.013

2015-01-01

Abstract:Objective To evaluate the efficacy and safety of febuxostat compared to allopurinol for the treatment of gout.Methods Randomized controlled trials ( RCTs ) of febuxostat were retrieved from PubMed , EmBase , the Cochrane Library , CNKI and CBM databases.Two revie-wers independently selected studies , assessed study quality , and extrac-ted data.According to the principles and methods of Cochrane systematic reviews , the included RCTs were analyzed by the software RevMan 5.2.7 provided by the Cochrane collaboration .Results Five studies were ulti-mately included in the analysis.Patients receiving febuxostat were more likely to achieve a serum uric acid ( sUA) of 6 mg· dL-1 than allopurinol recipients .The decline from baseline in sUA levels was more obvious in febuxostat group than allopurinol (P<0.05).However, febuxostat did not reduce the risk of gout flares compared with allopurinol .Overall , the risk of adverse drugs reaction was lower in febuxostat recipients than allopuri -nol.Conclusions Although febuxostat demonstrated a higher likelihood of achieving a target sUA level of <6 mg· dL-1 , however , there was no evidence that febuxostat is better than allopurinol for preventing gout flare .Taken its higher cost into consideration , febuxostat should not be the rou-tine option for chronic gout , except for those patients with renal dysfunction.
Transbilayer phospholipid flipping regulates Cdc42p signaling during polarized cell growth via Rga GTPase-activating proteins.

Koji Saito,K. Fujimura‐Kamada,H. Hanamatsu,U. Kato,M. Umeda,K. Kozminski,Kazuma Tanaka

DOI: https://doi.org/10.1016/J.DEVCEL.2007.09.014

IF: 13.417

2007-11-06

Developmental Cell

Abstract:

Neuroscience: Sensing calcium in red

Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease

Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta‐analysis

Urate‐lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink

Organization of the infraorbital nerve in rat: a quantitative electron microscopic study

Effect of febuxostat on adverse events and mortality in gout in Taiwan: An interrupted time series analysis

An Allopurinol-Controlled, Multicenter, Randomized, Double-Blind, Parallel Between-Group, Comparative Study Of Febuxostat In Chinese Patients With Gout And Hyperuricemia

Evaluation of febuxostat initiation during an acute gout attack: A prospective, randomized clinical trial

Febuxostat Therapy for Patients with Gout and Stage 2-4 CKD: a Retrospective Study

A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout

Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis

Effect and safety of febuxotant versus allopurinol in reducing serum urate in subjects with hyperuricemia and gout:a multi-center,randomized,double-blind,parallel controlled trail

Superiority of low‐dose benzbromarone to low‐dose febuxostat in a prospective, randomized comparative effectiveness trial in gout patients with renal uric acid underexcretion

Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis

The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study

Effect of the Xanthine Oxidase Inhibitor Febuxostat on the Cardio-Ankle Vascular Index in Asymptomatic Patients with Hyperuricemia and Liver Dysfunction: A Sub-Analysis of the PRIZE Study

Association Between Febuxostat Use and the Incidence of Cardiovascular Events, Mortality, and Kidney Events in Patients With Chronic Kidney Disease Compared to Allopurinol: A Study Using a Japanese Nationwide Database

Cardiovascular Safety of Febuxostat in Patients With Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials

Febuxostat leads to better cardiovascular outcomes compared to allopurinol in patients with advanced chronic kidney disease: A Population-based Cohort Study

Efficacy and safety of febuxostat versus allopurinol in the treatment of gout by Meta analysis

Transbilayer phospholipid flipping regulates Cdc42p signaling during polarized cell growth via Rga GTPase-activating proteins.